Full Text View
Tabular View
No Study Results Posted
Related Studies
Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy (PROACTIVE)
This study is ongoing, but not recruiting participants.
Study NCT00330863   Information provided by National Institute of Mental Health (NIMH)
First Received: May 26, 2006   Last Updated: November 20, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizophrenia
Schizoaffective Disorder
Additional conditions recognized in this trial
Psychotic Disorders
Recurrence
More general conditions related to this trial
Disease Attributes
Mental Disorders
Pathologic Processes
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
Risperidone microspheres
Risperidone
Olanzapine
Quetiapine
Ziprasidone
Aripiprazole
Paliperidone
Additional drug interventions recognized in this trial
9-hydroxy-risperidone
Antipsychotic Agents
More general drug interventions related to this trial
Antiemetics
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dopamine Agents
Dopamine Antagonists
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Serotonin Uptake Inhibitors
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
National Institute of Mental Health (NIMH)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services